Institut National De La Sante Et De La Recherche Medicale

Aventis Pharma S.a.

Axel Kahn

Sophie Vaulont

Jacques Mallet

Michel Perricaudet

Jean-Jacques Robert

Gaël Nicolas

Marc Peschanski

Gildas Le Gal La Salle

Fr&eacute;d&eacute;ric Revah

Georg Haase

Philippe Kennel

Bruno Doiron

Ruihuan Chen

The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia.

Use of hepcidin as a regulator of iron homeostasis

The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload, while inhibitors of hepcidin can he used in the treatment of anaemia.

The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anemia.

Hepcidin inhibitors for regulating iron homeostasis

The invention concerns a recombinant DNA vector characterized in that it is capable of directing the expression an/or transcription of a selected nucleotide sequence in the cells of the central nervous system and in that it comprises (i) at least part of the genome of an adenovirus, including the regions required for that adenovirus to penetrate into the cells normally infectable by that adenovirus and (ii) being inserted into said part of genome of an adenovirus under the control of a promoter, either present or also inserted into said genome part and operative in said cells. This recombinant vector finds particular use in the treatment of diseases of the central nervous system, also in gene therapy.

Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain

The invention concerns a novel method for treating motor neuron diseases and particularly amyotrophic lateral sclerosis. It consists more particularly in the systemic administration of expression systems of neurotrophic factors.

Method for treating amyotrophic lateral sclerosis

Assays for promoter operability in central nervous system cells

A defective recombinant virus including at least one heterologous gene controlled by a glucose-inducible expression signal, a pharmaceutical composition containing same, and cells transformed using said vector, are disclosed.

Growing community of inventors

Paris, France

Axel Kahn